Cue Biopharma (NASDAQ:CUE) Rating Increased to Hold at Zacks Research

Cue Biopharma (NASDAQ:CUE) was upgraded by investment analysts at Zacks Research to a “hold” rating in a research report issued to clients and investors on Monday, Zacks reports.

Other analysts also recently issued research reports about the stock. B. Riley Financial started coverage on shares of Cue Biopharma in a report on Friday. They set a “buy” rating and a $83.00 price objective on the stock. Wall Street Zen downgraded shares of Cue Biopharma from a “hold” rating to a “sell” rating in a research report on Sunday, August 23rd. Finally, Weiss Ratings lowered Cue Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 27th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $83.00.

Cue Biopharma Stock Performance

Cue Biopharma stock opened at $30.90 on Monday. The company has a market cap of $224.33 million, a P/E ratio of -1.14 and a beta of 2.45. Cue Biopharma has a one year low of $4.97 and a one year high of $45.50. The business has a fifty day moving average of $29.16 and a two-hundred day moving average of $98.05.

Cue Biopharma (NASDAQ:CUE) last posted its quarterly earnings results on Friday, August 14th. The company reported ($24.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.69) by ($22.45). The company had revenue of $7.88 million for the quarter, compared to analyst estimates of $3.00 million. Cue Biopharma had a negative return on equity of 620.06% and a negative net margin of 435.83%. Sell-side analysts predict that Cue Biopharma will post -32.12 EPS for the current year.

Insider Buying and Selling

In other Cue Biopharma news, insider Sumita Ray sold 8,829 shares of the firm’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $30.09, for a total transaction of $265,664.61. Following the completion of the transaction, the insider directly owned 118,545 shares in the company, valued at approximately $3,567,019.05. This trade represents a 6.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, VP Michael Vincent Meluzio sold 5,628 shares of Cue Biopharma stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $30.09, for a total transaction of $169,346.52. Following the transaction, the vice president owned 48,961 shares of the company’s stock, valued at approximately $1,473,236.49. The trade was a 10.31% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 72,715 shares of company stock worth $2,041,555 in the last three months. Corporate insiders own 14.56% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Northwestern Mutual Wealth Management Co. purchased a new stake in Cue Biopharma in the 2nd quarter valued at approximately $83,000. Texas Capital Bank Wealth Management Services Inc increased its position in Cue Biopharma by 1,231.2% during the fourth quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock worth $135,000 after buying an additional 407,568 shares in the last quarter. Bank of America Corp DE purchased a new position in Cue Biopharma during the second quarter worth $219,000. Seven Fleet Capital Management LP acquired a new position in shares of Cue Biopharma in the second quarter worth $338,000. Finally, Persistent Asset Partners Ltd acquired a new position in shares of Cue Biopharma in the second quarter worth $389,000. 35.04% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Cue Biopharma

Here are the key news stories impacting Cue Biopharma this week:

• Positive Sentiment: Strong Phase 2 efficacy: CUE-221 met the primary goal in a CSU study, with 54% of patients achieving complete hive resolution after 12 weeks. The result was reported as statistically significant versus Xolair, with p<0.005, supporting the candidate’s potential as a differentiated treatment. Cue Biopharma Meets Primary Goal in a Phase 2 Study of Chronic Hives Disease Drug Candidate
• Positive Sentiment: Large commercial opportunity and upcoming catalysts: Analysts highlighted CUE-221’s dual mechanism of action, its apparent efficacy relative to Xolair, and potential applications in CSU and food allergy. Investors may look ahead to 36-week pharmacokinetic and IgE data in 2026, followed by planned global Phase 2b/3 studies. Cue Biopharma: Initiating Buy Based on CUE-221 Trial Win
• Neutral Sentiment: Volatile market reaction: Coverage described an initial surge in CUE shares followed by swings as investors took profits. The unusually high trading volume reflects substantial repositioning after the clinical announcement rather than a new fundamental setback. Cue Biopharma Stock Swings After Positive CUE-221 Phase 2 Data
• Negative Sentiment: Execution and valuation risks remain: Despite the positive topline data, some coverage characterized the share-price decline after the initial rally as unwarranted, while the pullback underscores investor concerns about profit-taking, clinical-development risk, and the need to confirm durability in longer follow-up and later-stage trials. An Orexin Drug’s Proof of Concept in ADHD; Cue’s Unwarranted Share Slide

Cue Biopharma Company Profile

Cue Biopharma, Inc is a clinical-stage biotechnology company developing therapeutics that selectively activate and regulate antigen-specific T cells inside the body. Its approach is designed to direct the immune system toward cancer cells while potentially reducing the broad immune activation and toxicity associated with conventional immunotherapies.

The company’s proprietary Immuno-STAT (Selective Targeting of Antigens for Remodeling of T cells) platform uses biologic molecules that combine peptide-major histocompatibility complex components with immune-modulating signals.